Search Results
Search results for "Affiong Ika Oqua"
Results found for "Affiong Ika Oqua"
- Eleonora Comeo: Fluorescent Ligands and the Pharmacology of Adenosine Receptors | Dr. GPCR Ecosystem
It is also a matter of G protein coupling, tissue context, and the signaling assay used to measure affinity Affinity is not a fixed property - it is assay-dependent The apparent affinity of adenosine for its own A cAMP assay and a binding assay using the same receptor and the same ligand can return different affinity " and "high affinity" are assigned across the A2A and A2B subtypes. 4. differences, tumor microenvironment, and immune escape 22:08 Why affinity measurements shift depending
- Tuning GPCR System Sensitivity: Revealing True Drug Activity Through Functional Volume Control | Dr. GPCR Ecosystem
Terry Kenakin shows how tuning receptor expression separates affinity from efficacy, unmasks hidden agonism functional volume control, the deliberate tuning of system sensitivity, as a way to separate a ligand's true affinity Terry Kenakin will show how reducing sensitivity lets you measure affinity and relative efficacy and The same approach distinguishes what an allosteric modulator does to affinity versus efficacy, including From the Assay to the Candidate Reduce sensitivity and affinity separates from efficacy, so system-independent
- Sam Hoare: Receptor Residence Time and GPCR Data Analysis | Dr. GPCR Ecosystem
How receptor residence time — not affinity — rescued a CRF drug discovery program, and why a career in Sam Hoare: Receptor Residence Time and GPCR Data Analysis For most of GPCR pharmacology's history, affinity But affinity is a snapshot. The Off-Rate That Saved a Program Standard binding assays showed identical affinity. Across multiple programs — including work on a vesicular transporter where in vitro affinity at pH 7.4
- Brian Arey: Discovering Signaling Bias at the FSH Receptor | Dr. GPCR Ecosystem
stabilize different receptor conformations, which recruit different intracellular effectors with different affinities book is that the bimodal structure of receptor signaling - a ligand-binding pocket with one inherent affinity , and a cytoplasmic effector-binding pocket with its own independent affinity, both modulated by the
- How Lipid Rafts Organize GPCR Signaling | Dr. GPCR Ecosystem
affiliated with that institution, and his current research uses molecular docking to design higher affinity Sedaghat's group is using databases of natural bitter compounds and molecular docking to design higher affinity
- Dr. Nicola J. Smith | Dr. GPCR Ecosystem
inaccessible receptors to well-characterized and understood ‘unlocked’ therapeutic targets with high-affinity
- Ross Cheloha: Nanobody-GPCR Conjugates and the Engineering of Receptor Selectivity | Dr. GPCR Ecosystem
coupled and uncoupled states, and peptide analogs incorporating non-natural amino acids show differential affinity mechanistic process, and the tools to dissect it - bifunctional conjugates with independently tunable affinity
- Anita Nivedha: Computational Dynamics of Ligand Bias in GPCR Signaling | Dr. GPCR Ecosystem
from Subtle Structural Differences Even closely related receptor subtypes can display different ligand affinities and receptor pharmacology Using structural communication analysis to explain differences in ligand affinity and simulations, we explored how structural differences between receptor subtypes influence ligand affinity
- Fluorescent Probes for GLP-1R and GIPR Imaging: From Cell Assays to In Vivo Systems | Dr. GPCR Ecosystem
The company's portfolio is built around high-affinity, selective fluorescent ligands for GPCRs, supporting
- Eurofins Discovery GPCR Solutions | Drug Discovery & Development Partner | Dr. GPCR
Pharmacology & Binding Expertise cAMP, β-Arrestin, calcium flux, receptor internalization Radioligand binding, affinity
- GPCR Webinars | Dr. GPCR Ecosystem
determining the properties of a molecule Why testing agonists in low sensitivity systems separates affinity
- GPCR Assay Strategy, Bias, and Translational Drug Discovery | Dr. GPCR Ecosystem
antibodies required new ways of defining selectivity, assessing biophysical properties early, and treating affinity
- Maria Waldhoer: Pharmacological Fingerprints and the Limits of Bias | Dr. GPCR Ecosystem
fifteen pharmacological parameters — internalization rates, recycling and degradation rates, G protein affinity
- Kathryn Livingston: Allosteric Opioid Modulators and Receptor Signaling Beyond the Membrane | Dr. GPCR Ecosystem
characterize how these compounds operate - mapping whether activity is receptor-dependent, whether they shift affinity
- Robert J. Lefkowitz: Beta-Adrenergic Receptors, the GPCR Family, and Fifty Years of Discovery | Dr. GPCR Ecosystem
pharmacological toolkit deep enough to support radioligand synthesis, analog competition studies, and affinity
- The Practical Assessment of Signaling Bias | Dr. GPCR Ecosystem
Quantitative Approach 🔹 The operational model provides a structured way to measure bias, combining affinity












